Get started
Author

Olivier Adotévi

Observed names: A. Olivier, ADOTEVI Olivier, ADOTEVI, Olivier, Adotevi, Olivier, Adotévi, Olivier, O Adotevi, O Adotévi, O. Adotevi, O. Adotévi, Oliver Adotevi, Olivier Adotevi, Olivier Adotévi
Observed institutions: Inserm, Institut Pasteur, École Nationale Vétérinaire d'Alfort, Université de Bourgogne, Centre Hospitalier Universitaire de Besançon, Centre de Recherche des Cordeliers, Centre Georges François Leclerc, Assistance Publique – Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Université Bourgogne Franche-Comté, Établissement Français du Sang, Paris Cardiovascular Research Center, L'Hôpital Nord Franche-Comté, Hôpital Paul-Brousse, Centre d'Investigation Clinique de Besançon, Université Paris Descartes, Université Marie et Louis Pasteur, Interactions Hôte-Greffon-Tumeur & Ingénierie Cellulaire et Génique, Université Pierre-et-Marie-Curie, Institut Curie, Université de Franche-Comté
ORCID: 0000-0002-7742-136X
Observed ORCID: 0000-0002-7742-136X
OpenAlex ID: A5060518732
A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients
2010 · Olivier Adotevi, Helene Pere, et al. · Journal of Immunotherapy · 213
PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer
2018 · Magalie Dosset, Thaiz Rivera Vargas, et al. · OncoImmunology · 210
PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma
2018 · A. Asgarova, K. Asgarov, et al. · OncoImmunology · 199
PDF
A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens
2011 · Helene Pere, Yves Montier, et al. · Blood · 166
PDF
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study
2018 · Stefano Kim, Eric François, et al. · The Lancet Oncology · 143
Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
2021 · Florent Malard, Béatrice Gaugler, et al. · Blood Cancer Journal · 134
PDF
The B Subunit of Shiga Toxin Fused to a Tumor Antigen Elicits CTL and Targets Dendritic Cells to Allow MHC Class I-Restricted Presentation of Peptides Derived from Exogenous Antigens
2000 · Nacilla Haicheur, Emmanuelle Bismuth, et al. · The Journal of Immunology · 131
PDF
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
2019 · Francine Garnache-Ottou, Chrystelle Vidal, et al. · Blood Advances · 122
PDF
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
2023 · Marion Thibaudin, Jean-David Fumet, et al. · Nature Medicine · 112
PDF
Analysis of Spontaneous Tumor-Specific CD4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response
2012 · Yann Godet, Elizabeth Fabre, et al. · Clinical Cancer Research · 109
Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer
2012 · Helene Pere, Corinne Tanchot, et al. · OncoImmunology · 104
Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer
2019 · Caroline Laheurte, Magalie Dosset, et al. · British Journal of Cancer · 99
PDF
CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor–Engineered T Cells
2018 · Walid Warda, Fabrice Larosa, et al. · Cancer Research · 95
The Shiga toxin B‐subunit targets antigen in vivo to dendritic cells and elicits anti‐tumor immunity
2006 · Benoit Vingert, Olivier Adotevi, et al. · European Journal of Immunology · 90
PDF
Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape
2020 · Loria Zalmaï, Pierre-Julien Viailly, et al. · Haematologica · 81
PDF
The Human Cytomegalovirus Strain DB Activates Oncogenic Pathways in Mammary Epithelial Cells
2018 · Amit Kumar, Manoj Kumar Tripathy, et al. · EBioMedicine · 80
PDF
PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy
2020 · Sylvain Simon, Valentin Voillet, et al. · Journal for ImmunoTherapy of Cancer · 77
PDF
Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor
2012 · Magalie Dosset, Yann Godet, et al. · Clinical Cancer Research · 72
Analysis and Characterization of Antitumor T-cell Response After Administration of Dendritic Cells Loaded With Allogeneic Tumor Lysate to Metastatic Melanoma Patients
2008 · Nadege Bercovici, Nacilla Haicheur, et al. · Journal of Immunotherapy · 71
B Subunit of Shiga Toxin-Based Vaccines Synergize with α-Galactosylceramide to Break Tolerance against Self Antigen and Elicit Antiviral Immunity
2007 · Olivier Adotevi, Benoit Vingert, et al. · The Journal of Immunology · 64
A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
2019 · Luis Teixeira, Jacques Medioni, et al. · Clinical Cancer Research · 63
Lentiviral Vectors Encoding HIV-1 Polyepitopes Induce Broad CTL Responses In Vivo
2007 · Maria Candela Iglesias, Karine Mollier, et al. · Molecular Therapy · 61
PDF
Harnessing Antitumor CD4+ T Cells for Cancer Immunotherapy
2022 · Myriam Ben Khelil, Yann Godet, et al. · Cancers · 58
PDF
Cancer vaccines: designing artificial synthetic long peptides to improve presentation of class I and class II T cell epitopes by dendritic cells
2019 · Catherine Rabu, Laurie Rangan, et al. · OncoImmunology · 57
PDF
Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis
2021 · Florian Renosi, Anne Roggy, et al. · Blood Advances · 56
Works count: 379
Citation count: 4,761
H-index: 40
I10-index: 86
Year
Topic
Type